Neuroendocrine Tumors

About Neuroendocrine Tumors

Neuroendocrine tumors (NETs) are a group of rare and heterogeneous malignancies, most commonly arise from neuroendocrine cells of the gastrointestinal tract (particularly pancreas and small bowel), followed by lung, liver, and thymus. While most NETs are more indolent than other epithelial malignancies, poorly differentiated NETs can become aggressive and resistant to therapy. The PI3K/AKT/mTOR signaling pathway plays a central role in the pathogenesis and progression of NETs [1] and clinical studies [RADIANT1-4] demonstrated safety and efficacy of mTOR inhibitors in patients with NET.

A phase 2 pilot study is currently investigating the utility of ABI-009 as single agent in in patients with metastatic, unresectable, low or intermediate grade neuroendocrine tumors of the lung or gastroenteropancreatic system (NCT03670030).

1. Chan et al., Therap Adv Gastroenterol 2017 10(1): 132-141.

Neuroendocrine Tumors

March, 7 2019, Aadi Bioscience, Inc. (Aadi), For the first time in his life, Shanahan “Shanny” Dameral, 19, has a girlfriend. Soon, he’ll be graduating with a high school diploma and looking for his first job on the Kitsap Peninsula. What seems routine for many is a big deal for Dameral and other children living with treatment-resistant or intractable epilepsy. For reasons largely unknown, seizures in this subset of children persist long past their discovery in early childhood despite being treated with multiple medications and undergoing surgery to remove the affected parts of their brain. Diagnosed with epilepsy at age 5, life for Dameral has always come with seizures attached. When his seizures returned after a second brain surgery shortly after his 16th birthday, his mom Linley Allen, hoped for a medical breakthrough. “We needed to find something else since another surgery was out of the question,” Allen said. “We had heard about a drug being studied for a more severe seizure condition. I kept holding onto hope that it might be expanded to treat Shanny’s type of seizures because it was all we had at the time.”   See all and the original News article here: New Drug Trial Gives Hope for Treatment-Resistant Epilepsy